Johnson & Johnson Stock Goes Into Full Breakdown

Johnson & Johnson (JNJ) is in full breakdown mode today. The stock is off nearly 2% at midday Tuesday as the steep post-election pullback extends to over 8%. Johnson & Johnson stock is now taking out the October low and appears headed lower before a solid bottom can be reached. In the near term, J&J investors will likely see lower entry opportunities.

Back on Nov. 9, Johnson & Johnson exploded to the upside with the help of a huge breakout gap. Shortly after the opening bell that day, the stock was trading above both its September and October highs. This very powerful move left behind a solid base near the 200-day moving average, setting the stage for a fresh rally leg.

Unfortunately for the bulls, J&J immediately began to fade, and by the end of last week, shares were once again testing the 200-day moving average. This week, the stock is taking out key support near this long-term indicator.

On Tuesday, Johnson & Johnson is testing the October low near $113. This is a key level to monitor. A close below this area at the end of November would leave behind a key monthly downside reversal. In the aftermath, a deep selloff followed by a prolonged basing process is likely.

For patient investors, this continued weakness would lead to a very low-risk entry opportunity. Johnson & Johnson has a major support zone in place between $109.50 and $107. This key area includes the 2014 and 2015 highs and should be considered a buy zone.

Click here to see the below chart in a new window.

This article is commentary by an independent contributor. At the time of publication, the author was long JNJ.

If you liked this article you might like

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

The Decline In Johnson & Johnson Could Be Close to Being Over

The Decline In Johnson & Johnson Could Be Close to Being Over

Opioid Litigants Get Boost From Senate Report

Opioid Litigants Get Boost From Senate Report